Browse > Article
http://dx.doi.org/10.4046/trd.2009.66.6.444

The Role and Significance of Biomarker for Plasma G-CSF in Patients with Primary Lung Cancer  

Song, Jung Sub (Department of Internal Medicine, Wonkwang University College of Medicine)
Kim, So Young (Department of Internal Medicine, Wonkwang University College of Medicine)
Jo, Hyang Jeong (Department of Pathology, Wonkwang University College of Medicine)
Lee, Kang Kyoo (Department of Therapeutic Radiology & Oncology, Wonkwang University College of Medicine)
Shin, Jeong Hyun (Department of Internal Medicine, Wonkwang University College of Medicine)
Shin, Seong Nam (Department of Internal Medicine, Wonkwang University College of Medicine)
Kim, Dong (Department of Internal Medicine, Wonkwang University College of Medicine)
Park, Seong Hoon (Department of Radiology, Wonkwang University College of Medicine)
Lee, Young Jin (Department of Clinical Pathology, Wonkwang University College of Medicine)
Ko, Chang Bo (Good Cell Life, Inc.)
Lee, Mi Kung (Department of Thoracic Surgery, Wonkwang University College of Medicine)
Choi, Soon Ho (Department of Thoracic Surgery, Wonkwang University College of Medicine)
Jeong, Jong Hoon (Department of Internal Medicine, Wonkwang University College of Medicine)
Park, Jung Hyun (Department of Internal Medicine, Wonkwang University College of Medicine)
Kim, Hui Jung (Department of Internal Medicine, Wonkwang University College of Medicine)
Kim, Hak Ryul (Department of Internal Medicine, Wonkwang University College of Medicine)
Jeong, Eun Taik (Department of Internal Medicine, Wonkwang University College of Medicine)
Yang, Sei Hoon (Department of Internal Medicine, Wonkwang University College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.66, no.6, 2009 , pp. 444-450 More about this Journal
Abstract
Background: Biomarkers for cancer have several potential clinical uses, including the following: early cancer detection, monitoring for recurrence prognostication, and risk stratification. However, no biomarker has been shown to have adequate sensitivity and specificity. Many investigators have tried to validate biomarkers for the early detection and recurrence of lung cancer. To evaluate plasma G-CSF as such a biomarker, protein levels were measured and were found to correlate with the clinicopathological features of primary lung tumors. Methods: Between December 2006 and May 2008, 100 patients with histologically-validated primary lung cancer were enrolled into this study. To serve as controls, 127 healthy volunteers were enrolled into this study. Plasma G-CSF levels were measured in lung cancer patients using the sandwich ELISA system (R & D inc.) prior to treatment. Results: The mean plasma G-CSF levels were 12.2$\pm$0.3 pg/mL and 46.0$\pm$3.8 pg/mL (mean$\pm$SE) in the normal and in the cancer groups, respectively. In addition, plasma G-CSF levels were higher in patients with early lung cancer than in healthy volunteers (p<.001). Plasma G-CSF levels were higher in patients who were under 65 years old or smokers. Within the cancer group, plasma G-CSF levels were higher in patients with non small cell lung cancer than in patients with small cell lung cancer (p<.05). Overall, plasma G-CSF levels were shown to increase dependent upon the type of lung cancer diagnsosed. In the order from highest to lowest, the levels of plasma G-CSF tended to decrease in the following order: large cell carcinoma, squamous cell carcinoma, adenocarcinoma, and bronchioloalveolar carcinoma. Plasma G-CSF levels tended to be higher in patients with advanced TNM stage than in localized TNM stage (I, II
Keywords
Biological markers; Lung neoplasms; Granulocyte colony-stimulating factor; Metastasis;
Citations & Related Records

Times Cited By SCOPUS : 1
연도 인용수 순위
  • Reference
1 Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991;99: 1425-32   DOI   ScienceOn
2 Muller LC, Gasser R, Huber H, Klingler A, Salzer GM. Neuron-specific enolase (NSE) in small-cell lung cancer: longitudinal tumors marker evaluation. Lung Cancer 1992;8:29-36   DOI   ScienceOn
3 Miyagawa K, Chiba S, Shibuya K, Piao YF, Matsuki S, Yokota J, et al. Frequent expression of receptors for granulocyte-macrophage colony-stimulating factor on human nonhematopoietic tumor cell lines. J Cell Physiol 1990;143:483-7   DOI   PUBMED
4 Body JJ, Sculier JP, Raymakers N, Paesmans M, Ravez P, Libert P, et al. Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer 1990;65:1552-6   DOI   ScienceOn
5 Mroczko B, Szmitkowski M, Okulczyk B. Granulocytecolony stimulating factor (G-CSF) and macrophagecolony stimulating factor (M-CSF) in colorectal cancer patients. Clin Chem Lab Med 2002;40:351-5   DOI   ScienceOn
6 Mroczko B, Szmitkowski M. Hematopoietic cytokines as tumor markers. Clin Chem Lab Med 2004;42:1347-54   DOI   ScienceOn
7 Asano S, Urabe A, Okabe T, Sato N, Kondo Y. Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood 1977;49:845-52   PUBMED
8 Sculier JP, Body JJ, Jacobowitz D, Fruhling J. Value of CEA determination in biological fluids and tissues. Eur J Cancer Clin Oncol 1987;23:1091-3   DOI   ScienceOn
9 Yee LD, Liu L. The constitutive production of colony stimulating factor 1 by invasive human breast cancer cells. Anticancer Res 2000;20:4379-83   PUBMED
10 Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992;80:374-81   PUBMED
11 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108   DOI   ScienceOn
12 Tani K, Ozawa K, Ogura H, Shimane M, Shirafuji N, Tsuruta T, et al. Expression of granulocyte and granulocyte macrophage colony-stimulating factors by human non-hematopoietic tumor cells. Growth Factors 1990;3:325-31   DOI   ScienceOn
13 Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role. Chest 1995;108:163-9   DOI   ScienceOn
14 Bonomi P, Gale M, Rowland K, Taylor SG 4th, Purl S, Reddy S, et al. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys 1991;20:247-52   DOI   PUBMED   ScienceOn
15 Buccheri G, Ferrigno D. Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer. Chest 1988;93:565-70   DOI   ScienceOn
16 Kobashi Y, Okimoto N, sakamoto K. Squamous cell carcinoma of the lung producing granulocyte colonystimulating factor and resembling a malignant pleural mesothelioma. Intern Med 2004;43:111-6   DOI   ScienceOn
17 Watari K, Asano S, Shirafuji N, Kodo H, Ozawa K, Takaku F, et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989;73:117-22   PUBMED
18 Usami N, Uchiyama M, Kawaguchi K, Yasuda A, Ito S, Yokoi K. Granulocyte colony-stimulating factor-producing malignant pleural mesothelioma. J Thorac Oncol 2007;2:257-8   DOI   ScienceOn
19 Tsuruta N, Yatsunami J, Takayama K, Nakanishi Y, Ichinose Y, Hara N. Granulocyte-macrophage-colony stimulating factor stimulates tumor invasiveness in squamous cell lung carcinoma. Cancer 1998;82:2173-83   DOI   ScienceOn
20 Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225S-33S   PUBMED
21 McDermott RS, Deneux L, Mosseri V, Védrenne J, Clough K, Fourquet A, et al. Circulating macrophage colony stimulating factor as a marker of tumor progression. Eur Cytokine Netw 2002;13:121-7   PUBMED
22 Buccheri G, Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer 2001;34 Suppl 2:S65-9
23 Karnak D, Ulubay G, Kayacan O, Beder S, Ibis E, Oflaz G. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas. Lung 2001;179: 57-65   DOI   ScienceOn
24 Mino N, Iio A, Hamamoto K. Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs. Cancer 1988;62:730-4   DOI   ScienceOn
25 Hasegawa S, Suda T, Negi K, Hattori Y. Lung large cell carcinoma producing granulocyte-colony stimulating factor. Ann Thorac Surg 2007;83:308-10   DOI   ScienceOn
26 Cooper DL. Tumor markers. In: Goldman L, Bennett JC, editors. Cecil textbook of medicine. 21st ed. Philadelphia: W.B. Saunders company; 2000. p. 1039-42
27 Akoun GM, Scarna HM, Milleron BJ, Bénichou MP, Herman DP. Serum neuron-specific enolase: a marker for disease extent and response to therapy for smallcell lung cancer. Chest 1985;87:39-43   DOI   ScienceOn
28 Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B, Laszewicz W, et al. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007; 380:208-12   DOI   ScienceOn